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In the previous issue of *Critical Care*, Tang and colleagues \[[@B1]\] offer a very novel systematic review of 12 studies of gene expression in blood of humans who have sepsis. The studies conclude that there was no discernable transition from a pro- to an anti-inflammatory expression pheno-type in whole blood in human sepsis. The authors posit that sepsis as a pro-inflammatory phenotype that shifts to an anti-inflammatory phenotype may be flawed. This provocative conclusion disagrees with the evidence (animal and clinical); furthermore, ongoing translational and clinical studies hinge on the premise that there is indeed a transition (at about days 3 to 5 of clinical sepsis) from a brisk pro-inflammatory to an anti-inflammatory phenotype.

The innate immune system is the \'hard-wired\' rapid response system of each individual \[[@B2]\]. The first step in recognition of microorganisms is that pattern recognition receptors (such as the Toll-like receptor family) bind to highly conserved molecules called pathogen-associated molecular proteins. Accordingly, Tang and colleagues \[[@B1]\] found that upregulation of pathogen recognition receptors and signal transduction pathways was a consistent theme in expression studies.

The review by Tang and colleagues \[[@B1]\] has strengths, including defined screening criteria, broad literature review, strict inclusion criteria, and transparent methods for assessing strengths and weaknesses of studies to say nothing of the research strengths of the authors. Further-more, the summary is presented in clear tables accessible to expert and non-expert readers alike.

There are other issues to consider in the review. First, one source of variation in gene expression studies in sepsis is variability in time from onset of sepsis to time of blood draw. The authors found no obvious pattern to suggest differences in gene expression over time. However, the only studies that can be sure of onset of sepsis are the human endotoxemia studies (because time of endotoxin administration is known). I do not think that there are enough studies of expression at different times; thus, the authors\' conclusion may be premature (but could be proven correct by studies designed to address this important hypothesis).

Another source of variation of gene expression is variability of tissue examined given that different tissues express different genes at the same time in sepsis. Whole blood is a mélange of tissues (a variety of leukocytes); therefore, one assesses a weighted sum of all leukocyte classes. Furthermore, leukocyte differential changes rapidly in sepsis; thus, variability in whole-blood gene expression over time could be confounded by changes in leukocyte differential. About half of the studies assessed peripheral mononuclear cells \[[@B3]-[@B8]\].

A third great source of variable gene expression in sepsis is heterogeneity of causes and microbiology of sepsis, yet expression may vary according to cause and microbiology. For example, only one study \[[@B9]\] compared Gram-positive with Gram-negative sepsis. None compared various community-acquired infections (for example, pneumonia versus peritonitis).

There are concerns regarding the quality of data in gene expression \[[@B10],[@B11]\]. Only three of these studies confirmed microarray data with an independent measurement of expression.

One interpretation of the summary in Table 4 is that the one study of pre-sepsis \[[@B12]\] found increased expression of pro-inflammatory genes and two of three studies of early sepsis (\[[@B7]\] and \[[@B13]\] but not \[[@B5]\]) found increased expression of pro-inflammatory genes. In contrast, in studies of late sepsis, three of six studies found increased expression of pro-inflammatory genes \[[@B8],[@B14],[@B15]\] whereas three of six studies found decreased expression of pro-inflammatory genes \[[@B9],[@B14],[@B16]\]. Thus, there is very limited evidence that there is early pro-inflammatory gene expression and then later, balanced pro- and anti-inflammatory gene expression.

The balance of pro- to anti-inflammatory gene expression is difficult to quantify. Do any studies attempt to quantitate a ratio of pro- to anti-inflammatory gene expression? Even such a simplistic approach ignores differing potency of different proteins. Is threefold expression of tumor necrosis factor-alpha really balanced biologically by threefold expression of interleukin-10?

Sample size is highly variable in the studies (n = 12 to 176) reviewed by Tang and colleagues \[[@B1]\]. Sample size is clearly important, especially in studies with many outcome variables (gene expression levels). We need to know how often power and sample size were calculated and how often statistical power was adequate with adjustments for multiple comparisons. This is important since the main story of Tang and colleagues \[[@B1]\] is negative: there is no evidence of a clear pro- and then anti-inflammatory pattern of gene expression. Yet this could be a false negative if the studies were under-powered for such a question.

I agree with Tang and colleagues \[[@B1]\] that the variability in the quality of statistical methods in studies of gene expression in human sepsis is very important and deserves more emphasis in the literature and in reviews such as that of Tang and colleagues. Most non-expert readers need a deeper explanation of the statistical methods that are desirable and how these vary across studies.

Interestingly, Tang and colleagues do not comment on how therapies alter gene expression in sepsis \[[@B17]\].

In my opinion, the above limitations of studies and the authors\' summary of the literature require a leap of faith to suggest that the paradigm of sepsis as a pro-inflammatory phenotype that shifts to an anti-inflammatory phenotype is fundamentally flawed. In other words, the absence of evidence in these expression studies is not the same as having well-conducted studies with clear negative evidence. While Tang and colleagues may be on the right route, they have not reached the summit. There are tough and perhaps impassable cruxes ahead.
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